The record
| Class | growth factor |
|---|---|
| Also known as | PEGylated Mechano Growth Factor, PEG-IGF-1Ec, Pegylated MGF |
| Chain length | - |
| Molecular weight | 2,888.16 Da |
| Half-life | 48-72 hours (extended from minutes by PEGylation) |
| Route | SC or IM (site-specific injection into target muscle recommended) |
| Studied for | Muscle wasting conditions (sarcopenia), Post-injury muscle recovery, Soft tissue repair (tendons, ligaments), Post-stroke recovery, Cardiac repair after myocardial infarction |
| Research use | Muscle regeneration studies, Satellite cell activation research, Tissue repair mechanisms, Age-related muscle loss |
| What has been shown | Accelerated muscle repair and recovery; Increased satellite cell proliferation; Enhanced muscle hypertrophy; Bone healing promotion (demonstrated in rabbit models) |
| How it works | PEG-MGF is a PEGylated splice variant of IGF-1 (IGF-1Ec). It activates muscle satellite cells (muscle stem cells), causing them to proliferate and fuse with existing muscle fibers, promoting muscle hypertrophy and hyperplasia. The PEGylation extends half-life from minutes (native MGF) to hours/days by protecting from enzymatic degradation and retarding kidney filtration. |
| Patent status | check specific jurisdictions |
| Regulatory status | research only |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Muscle Hypertrophy / Anabolic Signaling (affection, 64%)
- Neuroprotection Signaling (affection, 37%)
- GH Pulsatility Environment (affection, 32%)
- Adult GH deficiency (illness, 30%)
- Anti-aging therapy (illness, 30%)
- Cardiac repair after myocardial infarction (illness, 100%)
- Duchenne muscular dystrophy (illness, 60%)
- Muscle wasting conditions (illness, 100%)
- Neuromuscular diseases (illness, 60%)
- Pediatric growth hormone deficiency (illness, 30%)
- Post-injury muscle recovery (illness, 100%)
- Post-stroke recovery (illness, 100%)
- Soft tissue repair (illness, 100%)
- Muscle loss or weakness (symptom, 67%)